Tag Archive for: solid tumours

Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours

/in

Funding to support development of first-in-class CLDN1 targeted medicines Strong syndicate of international life science investors One of the largest ADC-focused private fundraisings globally in 2024 Copenhagen, Denmark, 12 November 2024 – Novo Holdings, a leading global life science investor, today announced that it has co-led a $181.4 million Series D financing in Alentis Therapeutics (“Alentis”). […]

Read more

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM

/in

Collaboration with CSEM will speed up identification of suitable soluble TCR candidates Engimmune’s executive team will be presenting at Biotech Showcase in San Francisco in January Basel, Switzerland, December 13, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased to announce that it […]

Read more

IO Biotech, Inc. Announces $75 Million Private Placement Financing

/in

Offering includes participation from both new and existing healthcare-dedicated investors Proceeds extend the company’s cash runway into the fourth quarter of 2025 NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) — IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has […]

Read more

Leucid Bio and Great Ormond Street Hospital enter commercial agreement at new gene therapy manufacturing centre

/in

Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]

Read more